CN109259910A - A kind of multilayer coating film airway stent and preparation method thereof - Google Patents
A kind of multilayer coating film airway stent and preparation method thereof Download PDFInfo
- Publication number
- CN109259910A CN109259910A CN201810488480.9A CN201810488480A CN109259910A CN 109259910 A CN109259910 A CN 109259910A CN 201810488480 A CN201810488480 A CN 201810488480A CN 109259910 A CN109259910 A CN 109259910A
- Authority
- CN
- China
- Prior art keywords
- layer
- multilayer coating
- coating film
- electrostatic spinning
- thickness
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011248 coating agent Substances 0.000 title claims abstract description 39
- 238000000576 coating method Methods 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 239000002184 metal Substances 0.000 claims abstract description 71
- 229910052751 metal Inorganic materials 0.000 claims abstract description 71
- 239000003814 drug Substances 0.000 claims abstract description 58
- 238000010041 electrostatic spinning Methods 0.000 claims abstract description 50
- 229940079593 drug Drugs 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims description 48
- 238000002156 mixing Methods 0.000 claims description 29
- 239000012528 membrane Substances 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 17
- 238000002844 melting Methods 0.000 claims description 15
- 230000008018 melting Effects 0.000 claims description 15
- 238000011068 loading method Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 5
- 238000003618 dip coating Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 239000002861 polymer material Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 235000008429 bread Nutrition 0.000 claims 1
- 239000010410 layer Substances 0.000 abstract description 152
- 230000001886 ciliary effect Effects 0.000 abstract description 7
- 210000001519 tissue Anatomy 0.000 abstract description 7
- 206010028980 Neoplasm Diseases 0.000 abstract description 6
- 206010036790 Productive cough Diseases 0.000 abstract description 6
- 239000002345 surface coating layer Substances 0.000 abstract description 5
- 230000007547 defect Effects 0.000 abstract description 3
- 230000007812 deficiency Effects 0.000 abstract description 3
- 210000004400 mucous membrane Anatomy 0.000 abstract description 3
- 239000002344 surface layer Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 46
- 238000009987 spinning Methods 0.000 description 37
- 239000004372 Polyvinyl alcohol Substances 0.000 description 24
- 229920002451 polyvinyl alcohol Polymers 0.000 description 24
- 238000005491 wire drawing Methods 0.000 description 19
- 210000004379 membrane Anatomy 0.000 description 14
- -1 polytetrafluoroethylene Polymers 0.000 description 11
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 11
- 239000004810 polytetrafluoroethylene Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 229930012538 Paclitaxel Natural products 0.000 description 8
- 238000005253 cladding Methods 0.000 description 8
- 229960001592 paclitaxel Drugs 0.000 description 8
- 229920001610 polycaprolactone Polymers 0.000 description 8
- 239000004632 polycaprolactone Substances 0.000 description 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000004626 polylactic acid Substances 0.000 description 6
- 208000037803 restenosis Diseases 0.000 description 6
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 229920000747 poly(lactic acid) Polymers 0.000 description 5
- WPGUUPJOAVPZBQ-UHFFFAOYSA-N [Cl].OP(O)(O)=O Chemical compound [Cl].OP(O)(O)=O WPGUUPJOAVPZBQ-UHFFFAOYSA-N 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 4
- 229960002930 sirolimus Drugs 0.000 description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 238000009954 braiding Methods 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 190000008236 carboplatin Chemical compound 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 210000004081 cilia Anatomy 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 229960004635 mesna Drugs 0.000 description 2
- 239000007769 metal material Substances 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 239000004711 α-olefin Substances 0.000 description 2
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- 206010003598 Atelectasis Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 description 1
- 190000005734 Nedaplatin Chemical compound 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 229920004933 Terylene® Polymers 0.000 description 1
- GJMMXPXHXFHBPK-UHFFFAOYSA-N [P].[Cl] Chemical compound [P].[Cl] GJMMXPXHXFHBPK-UHFFFAOYSA-N 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229950005951 azasetron Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 108700004675 bleomycetin Proteins 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- QYOAUOAXCQAEMW-UTXKDXHTSA-N bleomycin A5 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCNCCCCN)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QYOAUOAXCQAEMW-UTXKDXHTSA-N 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229940113115 polyethylene glycol 200 Drugs 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000004579 taxol derivatives Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0076—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof multilayered, e.g. laminated structures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0023—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in porosity
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
Abstract
The present invention provides a kind of airway stent and preparation method thereof of multilayer coating film load medicine, coats layer 2-4, surface hole defect and the density degree difference of clad on the surface of metal net support using solution electrostatic spinning technique or melt electrostatic spinning technology.Metal net support ontology is a kind of tube of the hollow, surface with hole configurations.Surface coating layer is characterized in that the film layer from bracket surface layer to internal layer has gradient-structure, extexine is super loose reticular structure, secondary extexine is loose network structure, middle layer is un-densified porous network structure, and internal layer is film-form compact structure, and wherein at least having one layer is drug-loaded layer.By means of the invention it is possible to playing prevents tumor tissues to Intracavity, while providing space for the ciliary movement of airway surface, overcome common precoated metal airway stent because airway surface is capped, ciliary movement suppressed the deficiencies of leading to expectoration difficulties of mucous membrane；The thickness and the number of plies of drug-loaded layer are adjustable, and drugloading rate carries medicine than coating and is significantly improved.
Description
Technical field
The present invention relates to a kind of multilayer coating film airway stents and preparation method thereof, belong to medical instruments field, in particular to
It is a kind of to have the function of multilayer coating film structure, with the airway stent for carrying medicine, inhibiting for airway constriction expansion and air flue restenosis
And preparation method thereof.
Background technique
Chronic Obstructive Pulmonary Disease (COPD, chronic obstructive pulmonary disease) is that persistently existing respiratory symptom and air-flow are limited as feature
Chronic disease.China's patients with COPD sum is up to 80,000,000, and wherein patient with severe symptoms is more than 30,000,000,40 years old or more prevalence
Up to 8.2%；There are 2.5 people to die of chronic obstructive pulmonary disease per minute, annual death toll is more than 1,000,000.
Airway constriction is the most apparent pathological change feature of patients with COPD air flue, and narrow reason is by congenital or sense
Dye, wound, airway tumors or endobraonchial tuberculosis etc. cause, and can be divided into air flue malignant stricture according to cause and air flue is benign narrow
It is narrow.The clinical symptoms performance of airway constriction is different, depending on the degree of airway constriction, tempo and the cardio-pulmonary function of patient
Situation.Usual air flue luminal stenosis is more than 50% to be likely to occur apparent clinical symptoms, as lumen diameter≤10mm, then can be gone out
The now expiratory dyspnea of serious labour's property may occur in which the expiratory dyspnea of tranquillization as lumen diameter≤5mm.
After there is tracheae or bronchiostenosis, obstructive emphysema, obstructive pneumonia or the obstruction of secondary narrow section distal end
Property atelectasis, cause patient's repetitious stimulation cough, expectoration inability and chest to be blocked up uncomfortable in chest；Severe breathing can be caused tired when narrow serious
Difficult, respiratory failure is even dead, seriously threatens the life security of patient.Clinically frequently with tracheotomy, intubation or implantation branch
The methods of frame can release airway constriction, save patients ' lives.
The intracavitary interventional therapy of air flue is a kind of emerging minimally-invasive treatment, relatively low to the tolerance functional requirement of patient's cardiopulmonary, closely
The prefered method for the treatment of air flue benign stricture has been increasingly becoming over year.Currently, being clinically used for the bracket for the treatment of of airway constriction
Mainly by bare metal stent, metal air flue overlay film frame and metal air flue overlay film carried stent.
Metal airway stent stimulates greatly air flue, and there are blood coagulation complication, flexibilitys to mismatch, metallic foreign body permanently retains
In in vivo and in-stent restenosis incidence it is high the defects of.The main reason for causing air flue restenosis is easy damage after stenter to implant
Hurt airway mucus, cause the exceptions such as fibr tissue and smooth muscle tissue or hyperplasia, show as granulation tissue hyperplasia, causes to prop up
It is narrow once again in frame, seriously affect therapeutic effect.
Precoated metal bracket is that special film property material (polytetrafluoroethylene (PTFE), terylene, polyester, poly- amino are coated on metallic support
Ethyl formate etc.) bracket, not only remained the function of metallic support, but also the characteristic with film property material, bare metal branch can be overcome
Frame has that tumour and granulation grow into intracavitary and lead to restenosis.However, after air flue is capped, the ciliary movement of mucous membrane by
Suppression, is easy to cause expectoration difficulties.
Coating stent of medicine (DES) has many advantages, such as that targeting is good, local tissue concentration is high and Small side effects.The first generation
DES pharmaceutical carrier mainly uses non-degradable material, and main body rack is metal material；Second generation DES still use metal material for
Main body rack, pharmaceutical carrier is using biodegradable material such as polylactic acid, polycaprolactone etc..The drug of loading have sirolimus,
The anti-proliferate such as paclitaxel derivatives or antitumor class drug.However, that there are coating drug loads is limited, metal master bracket is long
Phase retention effects air flue function, minor are not suitable for and are implanted into the problems such as number is limited.
Summary of the invention
It is an object of the invention to overcome the deficiencies of the prior art and provide a kind of multilayer coating film airway stent and its preparation sides
Method.Multilayer coating structure, surface hole defect and the density degree difference of different clads are carried out on the surface of metal net support.
A kind of technical solution of use of the invention is as follows: a kind of multilayer coating film airway stent, including holey metal
Support tube body and the multilayer coating structure layer structure for being set to the holey metal support pipe surface, and the clad structure
It is middle at least one layer of for drug-loaded layer.
Wherein, holey metal support tube body surface coats layer 2-4 clad structure, and the clad is dredged by hole
The different membranoid substance of close degree and mesh composition, overall thickness are 35-76 μm.
Wherein, film layer of the clad structure from extexine to internal layer has gradient-structure and different-thickness.
Wherein, the extexine of clad structure is super loose reticular structure, and percent by volume >=60% shared by hole is thick
Degree is 20-40 μm.
Wherein, the secondary extexine of clad structure is loose network structure, percent by volume >=40% shared by hole, thickness
It is 10-20 μm.
Wherein, the middle layer of clad structure is un-densified porous network structure, and percent by volume >=20% shared by hole is thick
3-10 μm of degree.
Wherein, the internal layer of clad structure is general thin compact structure, percent by volume≤2% shared by hole, thickness
2-6μm。
The another technical solution of use of the invention is as follows: a kind of preparation method of multilayer coating film airway stent, comprising:
It dissolves by high molecular material heating melting or with solvent, is prepared using solution electrostatic spinning, melt electrostatic spinning or dip coating
The internal layer compact structure of clad structure；Clad structure is prepared using solution electrostatic spinning or melt electrostatic spinning mode
Outer layer to middle layer reticular structure；By drug and high molecular material blending drug-loading, there is mesh using electrostatic spinning technique preparation
The fibrous layer of structure is as medicine carrying membrane, and using medicine carrying membrane as wherein one layer of the extexine of clad structure to middle layer；It will preparation
Obtained internal layer compact structure, middle layer, secondary outer layer and extexine is successively covered on holey metal support tube body outer surface.
Wherein, it is by the method that internal layer compact structure is covered on holey metal support tube body outer surface: by high score
Sub- material molten impregnates metal net support 5 minutes, then takes out roll-in, cooling, solidifies obtained internal layer compact structure.
Wherein, prepare the method for medicine carrying membrane further include: by high molecular material be cortex, drug/high molecular material blend
For sandwich layer, medicine carrying membrane is prepared using melt coaxial electrostatic spinning or solution coaxial electrostatic spinning.
Wherein, the method for medicine carrying membrane is prepared further include: by drug and high molecular material dissolving and mixing, then use
Solution electrostatic spinning or solution coaxial electrostatic spinning prepare medicine carrying membrane.
Compared with existing metal film coated airway stent or metal coating carried stent, the present invention passes through metal net shaped branch
Frame provides support and anti-pressure ability, surface coating layer provide and carry medicine, barrier and porous space, has the advantages that
1, inner support tube is metallic netted structural, has good elasticity, mechanical support and anti-pressure ability, mechanical expansion narrow
Narrow air flue effect is good；
2, surface coats the clad that outer layer 2-3 has hole different with density degree, provides work for airway surface cilium
The problems such as moving place, avoiding overlay film frame that airway surface ciliary movement is hindered to cause air flue discomfort or unsmooth expectoration.
3, internal layer cladding in surface is a kind of film-form compact structure, can prevent tumor tissues intrusion internal stent from causing air flue
Restenosis；
4, the number of plies of drug-loaded layer and thickness are adjustable as needed, and drugloading rate is significantly improved than coating carried stent, and can be real
It is loaded while existing a variety of drugs.
Detailed description of the invention
Fig. 1 is a kind of structural schematic diagram of multilayer coating film airway stent provided by the invention.
Fig. 2 is a kind of super loose netted layer structure schematic diagram of multilayer coating film airway stent provided by the invention.
Fig. 3 is a kind of loose grid of multilayer coating film airway stent time layer structure schematic diagram provided by the invention.
Fig. 4 is a kind of un-densified porous media layer damage schematic diagram of multilayer coating film airway stent provided by the invention.
Fig. 5 is a kind of flow diagram of multilayer coating film airway stent preparation method provided by the invention.
Specific embodiment
Further more detailed description is made to technical solution of the present invention With reference to embodiment.Obviously, it is retouched
The embodiment stated is only a part of the embodiments of the present invention, instead of all the embodiments.Based on the embodiments of the present invention,
Those of ordinary skill in the art's every other embodiment obtained without creative labor, all should belong to
The scope of protection of the invention.
The present invention provides a kind of multilayer coating film airway stents, including holey metal to support tube body and be set to institute
The multilayer coating structure layer structure of holey metal support pipe surface is stated, and at least one layer of in the clad structure is drug-loaded layer.
As shown in Figure 1,1 supports tube body for holey metal, and 2 be multilayer coating structure layer structure, and 3 be the interior of compact structure in Fig. 1
Layer, 4 be un-densified porous middle layer, and 5 be loose grid time outer layer, and 6 be super loose netted outer layer.
Wherein, holey metal support tube body surface coats layer 2-4 clad structure, and the clad is dredged by hole
The different membranoid substance of close degree and mesh composition, overall thickness are 35-76 μm.
Wherein, film layer of the clad structure from extexine to internal layer has gradient-structure and different-thickness.
Wherein, the extexine of clad structure is super loose reticular structure, and percent by volume >=60% shared by hole is thick
Degree is 20-40 μm.As shown in Fig. 2, 61 being rack body in figure, 62 be super loose netted outer layer.
Wherein, the secondary extexine of clad structure is loose network structure, percent by volume >=40% shared by hole, thickness
It is 10-20 μm.As shown in figure 3,51 being rack body in figure, 52 be loose latticed secondary outer layer.
Wherein, the middle layer of clad structure is un-densified porous network structure, and percent by volume >=20% shared by hole is thick
3-10 μm of degree.
Wherein, the internal layer of clad structure is general thin compact structure, percent by volume≤2% shared by hole, thickness
2-6μm.As shown in figure 4,31 being rack body in figure, 32 be non-dense porous middle layer.
Multilayer coating film airway stent of the present invention is a kind of composite tube instrument, and metal net support ontology plays branch
Support effect, surface coating layer, which plays, to be loaded drug, prevents tumor tissues from providing to Intracavity, for the ciliary movement of airway surface
The effects of porous three-dimensional space, can overcome common precoated metal airway stent because airway surface is capped, the ciliary movement of mucous membrane
Suppressed the deficiencies of leading to expectoration difficulties.
The metal net support ontology is a kind of tube hollow, with hole configurations, it is characterized in that a kind of
Surface hollow-out or the perforated tubular object of metal mesh braiding, preferably network made of metal mesh braiding.
The surface coating layer can be prepared using non-degradable high molecular material and degradable high polymer material.Non- drop
Solve high molecular material such as polyvinyl acetate (EVA), polyacrylate (EMA), polyethylene (PE), polyethylene-alphaolefin copolymer
(POE), one or more mixture such as polypropylene-alpha olefin copolymer (POP).Degradable high polymer material such as polyvinyl alcohol
(PVA), one or more mixing such as polylactic acid (PLA), polycaprolactone (PCL), poly lactide-glycolide acid (PLGA)
Object.
As shown in figure 5, the present invention also provides a kind of preparation methods of multilayer coating film airway stent, comprising: by macromolecule
Material heating melting is dissolved with solvent, prepares clad knot using solution electrostatic spinning, melt electrostatic spinning or dip coating
The internal layer compact structure of structure；The outer layer of clad structure is prepared into using solution electrostatic spinning or melt electrostatic spinning mode
The reticular structure of layer；By drug and high molecular material blending drug-loading, there is mesh-structured fibre using electrostatic spinning technique preparation
Layer is tieed up as medicine carrying membrane, and using medicine carrying membrane as wherein one layer of the extexine of clad structure to middle layer；In being prepared
Layer compact structure, middle layer, secondary outer layer and extexine are successively covered on holey metal support tube body outer surface.
Wherein, it is by the method that internal layer compact structure is covered on holey metal support tube body outer surface: by high score
Sub- material molten impregnates metal net support 5 minutes, then takes out roll-in, cooling, solidifies obtained internal layer compact structure.
Wherein, prepare the method for medicine carrying membrane further include: by high molecular material be cortex, drug/high molecular material blend
For sandwich layer, medicine carrying membrane is prepared using melt coaxial electrostatic spinning or solution coaxial electrostatic spinning.
Wherein, the method for medicine carrying membrane is prepared further include: by drug and high molecular material dissolving and mixing, then use
Solution electrostatic spinning or solution coaxial electrostatic spinning prepare medicine carrying membrane.
It is that electrostatic spinning preparation carries for medicine carrying membrane and clad preparation method that the middle layer is at least one layer of into extexine
Medicine layer can be carried out using solution electrostatic spinning or melt electrostatic spinning technology.
The internal layer membrane shape dense layer preparation method is: (1) by high molecular material heating melting or with solvent it is molten
Solution prepares dense layer using dip coating；(2) it can also be coated using melting electrostatic spinning or solution electrostatic spinning, then be existed
It is toasted under high temperature or impregnates post-processing approach in a solvent and prepare dense layer.
The drug-loaded layer is characterized in loading one or more kinds of drugs, by drug and high molecular material blending drug-loading, so
There is mesh-structured fibrous layer using electrostatic spinning technique preparation afterwards；Or there is " skin-core " with the preparation of coaxial electrically spun technology
The porous network structure fibrous layer of structure, wherein cortex and sandwich layer can use: (1) high molecular material is cortex, drug/solvent
Mixture is sandwich layer；(2) high molecular material is cortex, drug/macromolecule mixture is sandwich layer.
The drug is antitumor platinum class such as oxaliplatin, carboplatin or Nedaplatin etc., interferes transcription and prevention
The drug such as Aclarubicin, Doxorubicin, mitoxantrone etc. of RNA synthesis, antibiotics such as bleomycin, bleomycin A5, mitogen
Mycin etc., anti-signal transduction medicine such as Tarceva, Gefitinib, Imatinib, Dasatinib etc., antitumor adjuvant such as A Li
Must benefit, Azasetron, Ondansetron, chlorine phosphoric acid, mesna etc., anti-tumour antibody medicine such as Rituximab, ibritumomab tiuxetan, west
One such or several compositions such as appropriate former times monoclonal antibody, bevacizumab.
Embodiment 1
Using EVA (VA content for 40%, melt flow index 60g/10min) is spinning material, by metal net shaped branch
Frame is fixed on the surface of rotation wire drawing device, spinneret and is coated on metal net shaped branch under conditions of 110 DEG C, under the random mode in far field
Frame surface coats the internal layer with a thickness of 2 μm, then takes the metal net support for being coated internal layer together with wire drawing device axis
Under, it is placed in 130 DEG C of baking ovens and toasts 10 minutes, then take out rapidly and the fast scroll back and forth on polytetrafluoroethylene film, obtain
Obtain fine and close internal layer.Secondly, the bracket for having coated internal layer is reloaded spinning machine, under conditions of 100 DEG C, the direct write mode of near field
Lower spinneret coats un-densified porous middle layer, coats with a thickness of 5 μm.Again, spinneret under conditions of 90 DEG C, under the direct write mode of near field
Loose grid time outer layer is coated, is coated with a thickness of 10 μm.Finally, using the mixture of EVA and taxol (mass ratio 90:10)
(uniform using mixing facilities melting mixing in advance), spinneret cladding is super loose netted outer under conditions of 90 DEG C, under Far Field Pattern
Layer coats with a thickness of 20 μm.
Embodiment 2
Using EVA (VA content for 20%, melt flow index 100g/10min) is spinning material, by metal net shaped branch
Frame is fixed on the surface of rotation wire drawing device, spinneret and is coated on metal net shaped branch under conditions of 110 DEG C, under the random mode in far field
Frame surface coats the internal layer with a thickness of 5 μm, then takes the metal net support for being coated internal layer together with wire drawing device axis
Under, it is placed in 130 DEG C of baking ovens and toasts 10 minutes, then take out rapidly and the fast scroll back and forth on polytetrafluoroethylene film, obtain
Obtain fine and close internal layer.Secondly, the bracket for having coated internal layer is reloaded spinning machine, under conditions of 100 DEG C, the direct write mode of near field
Lower spinneret coats un-densified porous middle layer, coats with a thickness of 10 μm.Again, it is sprayed under conditions of 90 DEG C, under the direct write mode of near field
Silk coats loose grid time outer layer, coats with a thickness of 20 μm.Finally, using EMA, (MA content 30%, melt flow index are
50g/10min) with the mixture of carboplatin (mass ratio 97:3) (in advance using mixing facilities melting mixing uniform), in 90 DEG C of item
Spinneret coats super loose netted outer layer under part, under Far Field Pattern, coats with a thickness of 20 μm.
Embodiment 3
Using POE (melt flow index 20g/10min) is spinning material, and metal net support is fixed on rotation and is received
The surface of silk device, spinneret and is coated on metal net support surface under conditions of 180 DEG C, under the random mode in far field, and cladding is thick
The internal layer that degree is 3 μm, then the metal net support for being coated internal layer is removed, be placed on 130 DEG C together with wire drawing device axis
It toasts 10 minutes, then takes out rapidly and the fast scroll back and forth on polytetrafluoroethylene film in baking oven, obtain fine and close internal layer.Its
It is secondary, the bracket for having coated internal layer is reloaded into spinning machine, uses the POP elastomer (melt flow index 10g/10min) to be
Spinning material, spinneret coats un-densified porous middle layer under conditions of 190 DEG C, under the direct write mode of near field, coats with a thickness of 5 μm.
Again, use PE for spinning material, spinneret coats loose grid time outer layer, packet under conditions of 190 DEG C, under the direct write mode of near field
It covers with a thickness of 15 μm.Finally, (mixed using mixing facilities melting in advance using the mixture of EVA and taxol (mass ratio 95:5)
Close uniform), spinneret coats super loose netted outer layer under conditions of 90 DEG C, under Far Field Pattern, coats with a thickness of 30 μm.
Embodiment 4
Using POE (melt flow index 20g/10min) is spinning material, and metal net support is fixed on rotation and is received
The surface of silk device, spinneret and is coated on metal net support surface under conditions of 180 DEG C, under the random mode in far field, and cladding is thick
The internal layer that degree is 3 μm, then the metal net support for being coated internal layer is removed, be placed on 130 DEG C together with wire drawing device axis
It toasts 10 minutes, then takes out rapidly and the fast scroll back and forth on polytetrafluoroethylene film in baking oven, obtain fine and close internal layer.Its
It is secondary, the bracket for having coated internal layer is reloaded into spinning machine, use EVA (VA content for 20%, melt flow index 100g/
It 10min) is spinning material, spinneret coats un-densified porous middle layer under conditions of 90 DEG C, under the direct write mode of near field, coats thickness
It is 10 μm.Again, the mixture of EVA (VA content for 20%, melt flow index 100g/10min) with sirolimus are used
(mass ratio 95:5 uses mixing facilities melting mixing uniform in advance) for spinning material, under conditions of 90 DEG C, the direct write mould of near field
Spinneret coats un-densified porous middle layer under formula, coats with a thickness of 20 μm.Finally, using EVA and taxol (mass ratio 92:8)
Mixture (using mixing facilities melting mixing uniform in advance) is spinning material, under conditions of 90 DEG C, spinneret under near field mode
Super loose netted outer layer is coated, is coated with a thickness of 40 μm.
Embodiment 5
Using medical grade PLGA (melt flow index 20g/10min) is spinning material, and metal net support is fixed
On the surface of rotation wire drawing device, spinneret and metal net support table is coated under conditions of 180 DEG C, under the random mode in far field
Face coats the internal layer with a thickness of 5 μm, then removes the metal net support for being coated internal layer together with wire drawing device axis,
It is placed in 130 DEG C of baking ovens and toasts 10 minutes, then take out rapidly and the fast scroll back and forth on polytetrafluoroethylene film, caused
Close internal layer.Secondly, the bracket for having coated internal layer is reloaded spinning machine, using PLA, (meso, melt flow index are
It 30g/10min) is spinning material, spinneret coats un-densified porous middle layer, packet under conditions of 150 DEG C, under the direct write mode of near field
It covers with a thickness of 10 μm.Again, the mixture (mass ratio of PCL (melt flow index 30g/10min) Yu sirolimus are used
90:10 uses mixing facilities melting mixing uniform in advance) for spinning material, under conditions of 120 DEG C, under the direct write mode of near field
Spinneret coats un-densified porous middle layer, coats with a thickness of 20 μm.Finally, using the mixing of PCL and taxol (mass ratio 90:10)
Object (using mixing facilities melting mixing uniform in advance) is spinning material, and spinneret coats under conditions of 140 DEG C, under near field mode
Super loose netted outer layer coats with a thickness of 30 μm.
Embodiment 6
Using medical grade PLGA (melt flow index 20g/10min) is spinning material, and metal net support is fixed
On the surface of rotation wire drawing device, spinneret and metal net support table is coated under conditions of 180 DEG C, under the random mode in far field
Face coats the internal layer with a thickness of 6 μm, then removes the metal net support for being coated internal layer together with wire drawing device axis,
It is placed in 130 DEG C of baking ovens and toasts 10 minutes, then take out rapidly and the fast scroll back and forth on polytetrafluoroethylene film, caused
Close internal layer.Secondly, the bracket for having coated internal layer is reloaded spinning machine, using PLA, (meso, melt flow index are
It 30g/10min) is spinning material, spinneret coats un-densified porous middle layer, packet under conditions of 150 DEG C, under the direct write mode of near field
It covers with a thickness of 10 μm.Again, the mixture (mass ratio of PCL (melt flow index 30g/10min) Yu sirolimus are used
90:10 uses mixing facilities melting mixing uniform in advance) for spinning material, under conditions of 120 DEG C, under the direct write mode of near field
Spinneret coats un-densified porous middle layer, coats with a thickness of 20 μm.Finally, using PCL for cortex, taxol and polyethylene glycol 200
The mixing level sandwich layer (use stir evenly in advance) of (mass ratio 20:80) is spinning material, under conditions of 120 DEG C, far field
Coaxial spinneret is carried out under mode and coats super loose netted outer layer, is coated with a thickness of 40 μm.
Embodiment 7
Using medical grade PLGA (melt flow index 20g/10min) is spinning material, and metal net support is fixed
On the surface of rotation wire drawing device, spinneret and metal net support table is coated under conditions of 180 DEG C, under the random mode in far field
Face coats the internal layer with a thickness of 6 μm, then removes the metal net support for being coated internal layer together with wire drawing device axis,
It is placed in 130 DEG C of baking ovens and toasts 10 minutes, then take out rapidly and the fast scroll back and forth on polytetrafluoroethylene film, caused
Close internal layer.Secondly, the bracket for having coated internal layer is reloaded spinning machine, using PLA, (meso, melt flow index are
It 30g/10min) is spinning material, spinneret coats un-densified porous middle layer, packet under conditions of 150 DEG C, under the direct write mode of near field
It covers with a thickness of 15 μm.Again, use PCL (melt flow index 30g/10min) and taxol mixture (mass ratio 90:
10, use mixing facilities melting mixing uniform in advance) for spinning material, under conditions of 120 DEG C, spinneret under the direct write mode of near field
Loose netted outer layer is coated, is coated with a thickness of 30 μm.
Embodiment 8
Using EVA (VA content for 40%, melt flow index 60g/10min) is spinning material, by metal net shaped branch
Frame is fixed on the surface of rotation wire drawing device, spinneret and is coated on metal net shaped branch under conditions of 110 DEG C, under the random mode in far field
Frame surface coats the internal layer with a thickness of 6 μm, then takes the metal net support for being coated internal layer together with wire drawing device axis
Under, it is placed in 130 DEG C of baking ovens and toasts 10 minutes, then take out rapidly and the fast scroll back and forth on polytetrafluoroethylene film, obtain
Obtain fine and close internal layer.Finally, (using mixing facilities melting mixing in advance using the mixture of EVA and taxol (mass ratio 90:10)
Uniformly), spinneret coats super loose netted outer layer under conditions of 90 DEG C, under Far Field Pattern, coats with a thickness of 30 μm.
Embodiment 9
Pharmaceutical grade PLA is dissolved in and prepares the solution that concentration is 5% in hexafluoroisopropanol, metal net support is fixed on
The surface for rotating wire drawing device, using solution electrostatic spinning machine spinneret and is coated on metal net support surface, coats with a thickness of 4 μm
Internal layer, the metal net support for being coated internal layer is removed together with wire drawing device axis then, is soaked in hexafluoroisopropanol
Bubble 5 minutes, then takes out rapidly and the fast scroll back and forth on polytetrafluoroethylene film, obtains fine and close internal layer.Secondly, will cladding
The bracket of internal layer is packed into solution electrostatic spinning machine, with preparation concentration in pharmaceutical grade PLGA dissolution hexafluoroisopropanol be 5% it is molten
Liquid coats un-densified porous middle layer using solution high-voltage electrostatic spinning, coats with a thickness of 10 μm.Again, molten with pharmaceutical grade PLGA
Spinning solution (PLGA content 5%, content of taxol 1%) is prepared in solution hexafluoroisopropanol, using solution high-voltage electrostatic spinning, cladding
With a thickness of 20 μm.Finally, to prepare spinning solution (PLGA content 5%, ibritumomab tiuxetan in pharmaceutical grade PLGA dissolution hexafluoroisopropanol
Content 0.5%), super loose netted outer layer is coated using solution high-voltage electrostatic spinning, is coated with a thickness of 35 μm.
Embodiment 10
Pharmaceutical grade PVA is dissolved in and prepares the solution that PVA content is 10% in 90 DEG C of hot water, metal net support is soaked
Bubble 5 minutes, dries after taking-up, coats the internal layer with a thickness of 2 μm.Then it covers on wire drawing device axis, obtains fine and close internal layer.Secondly,
The bracket for having coated internal layer is packed into solution electrostatic spinning machine, is dissolved in pharmaceutical grade PVA in 90 DEG C of hot water and prepares spinning solution
(PVA content 5%) coats un-densified porous middle layer using solution high-voltage electrostatic spinning, coats with a thickness of 8 μm.Again, with medicinal
Grade PVA is dissolved in 90 DEG C of hot water and prepares spinning solution (PVA content 8%), using solution high-voltage electrostatic spinning, cladding with a thickness of
12μm.It prepares spinning solution finally, being dissolved in 70 DEG C of hot water with pharmaceutical grade PVA and chlorine phosphoric acid (PVA content 7%, chlorine phosphoric acid contains
1%), using solution high-voltage electrostatic spinning amount coats super loose netted outer layer, coat with a thickness of 30 μm.
Embodiment 11
Pharmaceutical grade PVA is dissolved in and prepares the solution that PVA content is 20% in 90 DEG C of hot water, metal net support is soaked
Bubble 5 minutes, dries after taking-up, coats the internal layer with a thickness of 4 μm.Then it covers on wire drawing device axis, obtains fine and close internal layer.Secondly,
The bracket for having coated internal layer is packed into solution electrostatic spinning machine, is dissolved in pharmaceutical grade PVA in 90 DEG C of hot water and prepares spinning solution
(PVA content 5%) coats un-densified porous middle layer using solution high-voltage electrostatic spinning, coats with a thickness of 15 μm.Again, with medicine
It is dissolved in grade PVA in 90 DEG C of hot water and prepares spinning solution (PVA content 8%), using solution high-voltage electrostatic spinning, coat thickness
It is 20 μm.Finally, being used using pharmaceutical grade PVA as cortex, chlorine phosphoric acid dissolved aqueous solution (PVA content 5%, chlorine phosphorus acid content 1%)
Coaxial solution high-voltage electrostatic spinning coats super loose netted outer layer, coats with a thickness of 30 μm.
Embodiment 12
Pharmaceutical grade PVA is dissolved in and prepares the solution that PVA content is 20% in 90 DEG C of hot water, metal net support is soaked
Bubble 5 minutes, dries after taking-up, coats the internal layer with a thickness of 6 μm.Then it covers on wire drawing device axis, obtains fine and close internal layer.Secondly,
The bracket for having coated internal layer is packed into solution electrostatic spinning machine, is dissolved in pharmaceutical grade PVA in 90 DEG C of hot water and prepares spinning solution
(PVA content 5%, mesna content 0.2%) coats un-densified porous middle layer using solution high-voltage electrostatic spinning, coats thickness
It is 10 μm.Again, it is dissolved in pharmaceutical grade PVA in 90 DEG C of hot water and prepares spinning solution (PVA content 5%, Rituximab content
0.1%) super loose netted outer layer, is coated using solution high-voltage electrostatic spinning, is coated with a thickness of 20 μm.
Compared with existing metal film coated airway stent or metal coating carried stent, the present invention passes through metal net shaped branch
Frame provides support and anti-pressure ability, surface coating layer provide and carry medicine, barrier and porous space, has the advantages that
1, inner support tube is metallic netted structural, has good elasticity, mechanical support and anti-pressure ability, mechanical expansion narrow
Narrow air flue effect is good；
2, surface coats the clad that outer layer 2-3 has hole different with density degree, provides work for airway surface cilium
The problems such as moving place, avoiding overlay film frame that airway surface ciliary movement is hindered to cause air flue discomfort or unsmooth expectoration.
3, internal layer cladding in surface is a kind of film-form compact structure, can prevent tumor tissues intrusion internal stent from causing air flue
Restenosis；
4, the number of plies of drug-loaded layer and thickness are adjustable as needed, and drugloading rate is significantly improved than coating carried stent, and can be real
It is loaded while existing a variety of drugs.
What has been described above is only a preferred embodiment of the present invention, and present invention is not limited to the above embodiments.It is appreciated that this
Other improvements and changes that field technical staff directly exports or associates without departing from the basic idea of the present invention
It is considered as being included within protection scope of the present invention.
Claims (11)
1. a kind of multilayer coating film airway stent, which is characterized in that including holey metal support tube body and be set to described
Holey metal supports the multilayer coating structure layer structure of pipe surface, and at least one layer of in the clad structure is drug-loaded layer.
2. requiring the multilayer coating film airway stent according to right 1, which is characterized in that the holey metal support tube sheet
Body surface bread covers layer 2-4 clad structure, and the clad is made of the different membranoid substance of hole density degree and mesh, always
With a thickness of 35-76 μm.
3. requiring the multilayer coating film airway stent according to right 2, which is characterized in that the clad structure from extexine to
The film layer of internal layer has gradient-structure and different-thickness.
4. requiring the multilayer coating film airway stent according to right 2, which is characterized in that the extexine of the clad structure is
Super loose reticular structure, percent by volume >=60% shared by hole, with a thickness of 20-40 μm.
5. requiring the multilayer coating film airway stent according to right 2, which is characterized in that the secondary extexine of the clad structure
For loose network structure, percent by volume >=40% shared by hole, with a thickness of 10-20 μm.
6. requiring the multilayer coating film airway stent according to right 2, which is characterized in that the middle layer of the clad structure is non-
Dense porous reticular structure, percent by volume >=20% shared by hole, 3-10 μm of thickness.
7. requiring the multilayer coating film airway stent according to right 2, which is characterized in that the internal layer of the clad structure is general
Logical film compact structure, percent by volume≤2% shared by hole, 2-6 μm of thickness.
8. a kind of preparation method of multilayer coating film airway stent characterized by comprising
It is dissolved by high molecular material heating melting or with solvent, using solution electrostatic spinning, melt electrostatic spinning or dip coating
Prepare the internal layer compact structure of clad structure；
The outer layer of clad structure is prepared to the reticular structure in middle layer using solution electrostatic spinning or melt electrostatic spinning mode；
By drug and high molecular material blending drug-loading, have mesh-structured fibrous layer as load medicine using electrostatic spinning technique preparation
Film, and using medicine carrying membrane as wherein one layer of the extexine of clad structure to middle layer；
The internal layer compact structure being prepared, middle layer, secondary outer layer and extexine are successively covered on holey metal support tube
Body outer surface.
9. the preparation method of multilayer coating film airway stent according to claim 8, which is characterized in that by internal layer compact structure
The method for being covered on holey metal support tube body outer surface is: melt polymer material soaks metal net support
Bubble 5 minutes then takes out roll-in, cooling, solidifies obtained internal layer compact structure.
10. the preparation method of multilayer coating film airway stent according to claim 8, which is characterized in that prepare medicine carrying membrane
Method further include: by high molecular material be cortex, drug/high molecular material blend is sandwich layer, using melt coaxial electrostatic spinning
Silk or solution coaxial electrostatic spinning prepare medicine carrying membrane.
11. the preparation method of multilayer coating film airway stent according to claim 8, which is characterized in that prepare medicine carrying membrane
Method further include: then coaxially quiet using solution electrostatic spinning or solution by drug and high molecular material dissolving and mixing
Electrospun prepares medicine carrying membrane.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810488480.9A CN109259910A (en) | 2018-05-21 | 2018-05-21 | A kind of multilayer coating film airway stent and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810488480.9A CN109259910A (en) | 2018-05-21 | 2018-05-21 | A kind of multilayer coating film airway stent and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109259910A true CN109259910A (en) | 2019-01-25 |
Family
ID=65148005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810488480.9A Pending CN109259910A (en) | 2018-05-21 | 2018-05-21 | A kind of multilayer coating film airway stent and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109259910A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110141760A (en) * | 2019-06-05 | 2019-08-20 | 山东百多安医疗器械有限公司 | A kind of surface carries the vertebral plasty dilating sacculus and preparation method thereof of medicine |
| CN110215540A (en) * | 2019-04-09 | 2019-09-10 | 盐城工业职业技术学院 | A kind of fibroin with three-dimensional order and unordered dual network structure/polymer matrix tubular bracket and its preparation and application |
| CN114681682A (en) * | 2022-03-03 | 2022-07-01 | 宁波市第一医院 | Biological scaffold and preparation material and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009061021A (en) * | 2007-09-05 | 2009-03-26 | Univ Kansai | In vivo indwelling object including branched biodegradable polyester |
| CN102525697A (en) * | 2011-12-22 | 2012-07-04 | 上海纳米技术及应用国家工程研究中心有限公司 | Medicine-carrying membrane-covered stent and preparation method thereof |
| CN105287048A (en) * | 2014-07-03 | 2016-02-03 | 上海理工大学 | Filming support |
| CN107802377A (en) * | 2017-11-29 | 2018-03-16 | 成都创客之家科技有限公司 | A kind of titanium alloy film-coated vascular support |
| CN209595971U (en) * | 2018-05-21 | 2019-11-08 | 广州医科大学 | A kind of multilayer coating film airway stent |
-
2018
- 2018-05-21 CN CN201810488480.9A patent/CN109259910A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009061021A (en) * | 2007-09-05 | 2009-03-26 | Univ Kansai | In vivo indwelling object including branched biodegradable polyester |
| CN102525697A (en) * | 2011-12-22 | 2012-07-04 | 上海纳米技术及应用国家工程研究中心有限公司 | Medicine-carrying membrane-covered stent and preparation method thereof |
| CN105287048A (en) * | 2014-07-03 | 2016-02-03 | 上海理工大学 | Filming support |
| CN107802377A (en) * | 2017-11-29 | 2018-03-16 | 成都创客之家科技有限公司 | A kind of titanium alloy film-coated vascular support |
| CN209595971U (en) * | 2018-05-21 | 2019-11-08 | 广州医科大学 | A kind of multilayer coating film airway stent |
Non-Patent Citations (1)
| Title |
|---|
| 杜 娟: "气道内金属支架应用研究进展", 《临床荟萃》, vol. 20, no. 6, pages 355 - 357 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110215540A (en) * | 2019-04-09 | 2019-09-10 | 盐城工业职业技术学院 | A kind of fibroin with three-dimensional order and unordered dual network structure/polymer matrix tubular bracket and its preparation and application |
| CN110215540B (en) * | 2019-04-09 | 2021-07-27 | 盐城工业职业技术学院 | Silk fibroin/polymer based tubular stent with three-dimensional ordered and disordered double-network structure and preparation and use methods thereof |
| CN110141760A (en) * | 2019-06-05 | 2019-08-20 | 山东百多安医疗器械有限公司 | A kind of surface carries the vertebral plasty dilating sacculus and preparation method thereof of medicine |
| CN110141760B (en) * | 2019-06-05 | 2021-10-08 | 山东百多安医疗器械股份有限公司 | Centrum forming expansion balloon with drug loaded on surface and preparation method thereof |
| CN114681682A (en) * | 2022-03-03 | 2022-07-01 | 宁波市第一医院 | Biological scaffold and preparation material and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6300732B2 (en) | Medical device coated with rotating span material and method of manufacturing the same | |
| Darbasizadeh et al. | Electrospun Doxorubicin-loaded PEO/PCL core/sheath nanofibers for chemopreventive action against breast cancer cells | |
| CN102525697A (en) | Medicine-carrying membrane-covered stent and preparation method thereof | |
| US8883183B2 (en) | Medical devices incorporating collagen inhibitors | |
| CN109259910A (en) | A kind of multilayer coating film airway stent and preparation method thereof | |
| CN105457101B (en) | A kind of preparation method of three-decker small-caliber vascular stent | |
| CN106581752A (en) | Degradable medicine slow release function composite enteric stent and making method thereof | |
| CN101168073A (en) | Method for preparing electrostatic spinning fiber film-coated vascular inner rack | |
| CN109701080A (en) | 4 axis 3D printing tubular medical brackets of one kind and preparation method thereof | |
| CN209595971U (en) | A kind of multilayer coating film airway stent | |
| CN102151185A (en) | Biodegradable stent with laminated coatings | |
| CN106178121B (en) | X-ray developing blood vessel substitute and preparation method thereof | |
| CN105597163B (en) | Ferrous alloy implanted medical device and preparation method thereof | |
| CN103705325A (en) | Multilayer bionic intestinal stent and preparation method thereof | |
| KR101370607B1 (en) | Non-vascular drug-eluting stent membrane using electrospinning, and method for preparing the same | |
| JP2007268239A (en) | Artificial blood vessel | |
| WO2023083086A1 (en) | Drug-coated and drug-eluting balloon catheter, and preparation method therefor | |
| KR101271242B1 (en) | Preparation method of stent for photodynamic stent | |
| Khan et al. | Cellulose nanofibers as Scaffold-forming materials for thin film drug delivery systems | |
| Park et al. | Creation of a functional graded nanobiomembrane using a new electrospinning system for drug release control and an in vitro validation of drug release behavior of the coating membrane | |
| Eryildiz | Fabrication of drug-loaded 3D-printed bone scaffolds with radial gradient porosity | |
| CN102727331A (en) | Biodegradable magnesium alloy bile duct litholysis knitted bracket and preparation method thereof | |
| KR20120105116A (en) | Porous microparticles for prevention or treatment of pulmonary disease and method thereof | |
| CN104474595A (en) | Production method of dilayer compounding coated esophageal stent with esophageal cancer treatment assisting function | |
| KR101324772B1 (en) | An esophageal stent for controlled delivery of a drug and a preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20191226 Address after: 510555 room 206, 2f, building 2, No.1, Ruifa Road, Luogang District, Guangzhou City, Guangdong Province Applicant after: GUANGZHOU JIANKANGYUAN RESPIRATORY DRUG ENGINEERING TECHNOLOGY CO., LTD. Address before: 510170 Dongfeng West Road, Yuexiu District, Guangzhou, Guangdong Province, No. 195 Applicant before: Guangzhou medical university Applicant before: the First Affiliated Hospital of Guangzhou Medical University |